ELIGIBILITY AND PROTEOMIC CLUSTER PROFILES OF REAL-WORLD PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION IN LANDMARK SGLT2-INHIBITOR TRIALS | Publicación